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analysis from a societal perspective with a 3 month time horizon.
Direct medical costs (hospitalizations, drug therapies, specialist
visits, diagnostics, and laboratory exams) were quantiﬁed using
the National Health Service tariffs expressed in Euro 2005.
RESULTS: 220 patients were enrolled, 110 cases matched with
110 controls. The mean age was 66.0 years, 57.3% were male.
The mean total cost per patient-month was Euro 380.4 com-
pared to Euro 164.4 for cases and controls, respectively (P <
0.0001). On average, direct medical cost per patient-month was
estimated at Euro 368.6 in cases and Euro 149.8 in controls (P
< 0.0001). Hospitalizations accounted for the greatest propor-
tion of Health care costs in both groups, followed by drug ther-
apies (hospitalizations: 21.9% and 5.5%; drug therapies: 94.5%
and 68.2% in cases and controls, respectively). The working
ability reduction is higher in cases than in controls (P = 0.004).
CONCLUSION: The results of our analysis show that subjects
with cerebrovascular disease aged 40 to 79 years are more costly
than subjects without cerebrovascular diseases.
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OBJECTIVES: Clinical trials have shown that candesartan, an
angiotensin II receptor antagonist, improves survival and reduces
hospitalisation rates in patients with chronic heart failure (CHF)
and a reduced left ventricular ejection fraction (LVEF £ 40%).
This study assessed the cost-effectiveness of candesartan in the
management of CHF in Belgium. METHODS: Based on the 
outcomes (mortality, hospitalisation rate, cardiovascular events)
reported in the CHARM Programme (Candesartan in Heart
failure Assessment of Reduction in Mortality and morbidity), a
decision model was developed predicting the cost-effectiveness
of candesartan compared to placebo added to current standard
treatment (including diuretics, b-blockers, digoxin) of CHF. Two
populations with a LVEF £ 40% were analysed: those who were
intolerant of ACE-inhibitors (“alternative group”) and those
who were simultaneously treated with ACE-inhibitors (“added
group”). Direct costs from the health care payer’s perspective
(2004) were used. Effects were expressed as Life-Years gained
(LYG). The time horizon of the model was 3.14 years, based on
the follow up time in the CHARM programme, but also takes
into account that patients who survived the study period gain
life years and incur extra costs afterwards. An annual discount
of 3% was applied on costs and effects. The average cost per day
of candesartan (based on the average daily dose taken from the
CHARM-programme) was €1.06 in the “alternative” and €1.08
in the “added group”. RESULTS: The incremental cost-
effectiveness ratio was €1,214/LYG [95%CI €-8,365–€14,136]
in the “alternative” and €2,310/LYG [95%CI €425–€3,920] in
the “added” group. Sensitivity analysis showed the robustness of
the results. Monte Carlo analysis showed that, using a threshold
of €20,000/LYG, candesartan was cost-effective in 93.4% in the
“alternative” and in 99.8% in the “added” group. CONCLU-
SIONS: Administering candesartan to Belgian patients with a
LVEF £ 40% whether or not they are treated with ACE-
inhibitors seems cost-effective from the health care payer’s 
perspective.
CV4
DISCRETE EVENT SIMULATION OF THE ECONOMIC
CONSEQUENCES OF ADDING MANAGED VENTRICULAR
PACING MODE (DDDR-MVP) TO A STANDARD DUAL
CHAMBER PACEMAKER (DDDR) IN FRANCE
Deniz HB, Caro JJ,Ward AJ
Caro Research Institute, Concord, MA, USA
OBJECTIVE: To estimate the long-term economic and health
impact of managing bradycardia with DDDR-MVP instead of
standard dual chamber pacing (DDDR) in France. DDDR-MVP
can reduce the amount of ventricular pacing. This may be advan-
tageous since previous studies have shown that more frequent
pacing of the ventricle increases the risk for heart failure and
atrial ﬁbrillation. METHODS: A discrete event simulation was
developed to estimate effects over ﬁve years. Identical patient
pairs were created, one received DDDR-MVP, the other DDDR.
During the simulation, each patient may develop post-operative
complications, pacemaker syndrome, heart failure, atrial ﬁbril-
lation (which may become chronic and require anticoagulants),
or have a stroke. The risk proﬁles depend on the patient’s char-
acteristics, device type and cumulative ventricular pacing. The
cumulative proportion of time receiving ventricular pacing is
based on data collected during a randomized, single-blind cross-
over trial of these devices. Risk functions for the association of
ventricular pacing with heart failure and atrial ﬁbrillation were
based on published data from the MOST trial. Life expectancy
is assumed the same with either device. Costs obtained from hos-
pitalization (re-operation, heart failure, stroke), and anticoagu-
lation, are reported in 2004 € and discounted at 3%. Each
analysis was based on 100 replications. Sensitivity analyses
covered all inputs and assumptions. RESULTS: Within 5 years,
29.1% of the patients in each cohort died. Discounted costs over
5 years were about €13,000 per patient; despite the higher initial
cost of DDDR-MVP mean additional cost was only €274 per
patient. DDDR-MVP is predicted to increase QALY by a mean
0.05 years, yielding a mean cost-effectiveness ratio of
€5,360/QALY. Sensitivity analyses showed the results were con-
sistent over a wide range of values. CONCLUSION: Based on
these 5-year estimates, the additional health beneﬁts of MVP
provide very attractive value for patients with sinoatrial-node
disease or intermittent atrioventricular block.
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OBJECTIVES: To examine the relationship between the Inﬂam-
matory Bowel Disease questionnaire (IBDQ) total score and
measures of utility (EQ-5D and the SF-6D scores), and to esti-
mate algorithms to map the two utility values from IBDQ scores.
METHODS: A large dataset, from ENACT I and II multina-
tional, randomized, placebo controlled clinical trials in moder-
ate to severe Crohn’s disease, provided contemporaneous patient
responses to all three questionnaires. Paired observations from
multiple time-points for patients from both trials were combined
in the analysis. The mean utility scores by IBDQ score deciles
were estimated. Spearman correlation coefﬁcients were calcu-
